How to Buy Regeneron Pharmaceuticals Stock
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses.
Regeneron Pharmaceuticals stock last closed at $794.19, down 1.67% from the previous day, and has increased 37.02% in one year. It has overperformed other stocks in the Biotechnology industry by 0.53 percentage points. Regeneron Pharmaceuticals stock is currently +46.8% from its 52-week low of $541.00, and -6.23% from its 52-week high of $847.00.
There are currently 102.95M shares of REGN outstanding. The market capitalization of REGN is $81.77B. In the last 24 hours, 488,000 REGN shares were traded.
How to Buy Regeneron Pharmaceuticals Stock
Not sure how to invest in Regeneron Pharmaceuticals stock? Here's how.
- Figure out where to buy Regeneron Pharmaceuticals stock: You need to choose a stock brokerage, but don't worry - we've analyzed dozens of stock brokerages and apps to help you choose where to buy Regeneron Pharmaceuticals stock.
- Create your brokerage account: Sign up for 0% commission trading with the highest-rated brokerage we've identified.
- Deposit funds into your brokerage account: Pick your payment method and add your info.
- Research Regeneron Pharmaceuticals stock: The Regeneron Pharmaceuticals ticker symbol is REGN. Is Regeneron Pharmaceuticals stock a good investment? Should you buy shares of REGN? How do REGN's underlying business fundamentals look? Do top analysts think Regeneron Pharmaceuticals is a good buy? Why has REGN's stock price moved recently? (Hint: Our stock research tools can help you understand if REGN is a good stock to buy).
- Make your REGN buy order: Decide if you will purchase REGN shares at the current market price or use a limit order to purchase REGN shares at a particular price.
- Get key alerts regarding your REGN investment: Create a watchlist to keep tabs on your new investment in Regeneron Pharmaceuticals stock.
Step 1: Figure out where to buy Regeneron Pharmaceuticals stock
You need an online brokerage account in order to access the NASDAQ market and buy REGN stock.
Our recommended brokerage: eToro
We believe that eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to world markets: From Technology to Industrials, New York to London (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community of more than 20 million users globally. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by creating an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the right brokerage, you need to fill out some personal details so you can invest in REGN stock today.
How to Start a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal details to open a new brokerage account.
- Submit your application by clicking the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your brokerage account
Now that you've opened your account on the best free stock trading app, you need to deposit funds:
Watch the tutorial below to see the process of transferring funds into your new investment account.
Step 4: Research Regeneron Pharmaceuticals stock
After you have figured out the best place to buy Regeneron Pharmaceuticals stock, it's very important to evaluate their stock prior to buying, so you can comprehend the risk and upside.
Regeneron Pharmaceuticals stock quick numbers
REGN Due Diligence Checks
WallStreetZen was created to help average investors do better fundamental analysis.
You can see all of the due diligence checks on REGN's stock page.
Is REGN stock properly valued?
You can use many financial metrics, analyses, models, and charts to gauge REGN's fair value.
Using relative valuations metrics:
- REGN could be overvalued based on its P/E ratio of 18.94x, relative to Biotechnology industry P/E ratio of 16.84x
- REGN could be undervalued based on its P/B ratio of 2.58x, relative to Biotechnology industry P/B ratio of 5.46x
- REGN could be overvalued based on its PEG ratio of 1.01x
You can do additional valuation research on REGN's stock here.
A look at REGN Cashflows and Balance Sheet
Positive Health Checks:
- REGN earnings of $5.22B is not sufficient to cover its interest payments.
- REGN's operating cash flow of $4.68B allows it to safely service it's debt of $2.71B.
- There are more short-term assets than short-term liabilities on the REGN balance sheet.
- Total REGN debt is lower than 5 years ago, relative to shareholder equity.
- REGN has a low debt to equity ratio of 0.32.
- There are more short-term assets than long-term liabilities on the REGN balance sheet.
Negative Health Checks:
- REGN profit margin has gone down from 31.4% to 27.9% in the past year.
Do Wall Street analysts think it's a good time to buy REGN stock
Out of 19 sell side analysts who give ratings on REGN, the consensus analyst rating on Regeneron Pharmaceuticals is a Strong Buy
Please note that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent REGN Analyst Upgrades/Downgrades
Carter Gould, a top 11% analyst from Cantor Fitzgerald maintains REGN with a strong buy rating and raises their REGN price target from $750.00 to $795.00, on Jul 31, 2026.
Cantor Fitzgerald's Carter Gould raised their price target on Regeneron Pharmaceuticals (NASDAQ: REGN) by 6% from $750 to $795 on 2026/07/31. The analyst maintained their Strong Buy rating on the stock.
Regeneron reported its Q2 2026 earnings.
Raising their price target, Gould said the quarter's results successfully addressed near-term commercial uncertainty, headling Dupixent 's strong performance, and the Eylea franchise's momentum supporting improved visibility and valuation upside.
Earnings Report
For Q2 2026, Regeneron Pharmaceuticals reported:
- EPS of $14.29, which beat the Zacks Consensus Estimate of $10 and, by 11%, Q2 2025’s $12.89.
- Revenue of $4.29B, which beat the Zacks Consensus Estimate by 11.74% and, by 17%, Q2 2025’s $3.68B.
Management did not provide EPS and revenue guidance in its press release.
Board co-Chair, President, & CEO Leonard S. Schleifer, M.D., Ph.D. commented: "Regeneron delivered another quarter of strong financial performance, with double-digit top- and bottom-line growth reflecting the continued strength of our commercial portfolio and the potential of our pipeline.
"Of note, global Dupixent, global Libtayo, and U.S. EYLEA HD net product sales increased by 38%, 30%, and 52%, respectively, compared to Q2 2025.
“With approximately 50 clinical assets, we remain focused on translating our science into even more successful new medicines across a broad array of diseases."
Mohit Bansal, a top 11% analyst from Wells Fargo maintains REGN with a hold rating and raises their REGN price target from $700.00 to $750.00, on Jul 31, 2026.
Gregory Renza, a top 3% analyst from Truist Securities maintains REGN with a strong buy rating and raises their REGN price target from $769.00 to $772.00, on Jul 31, 2026.
Biren Amin, a bottom 6% analyst from Piper Sandler maintains REGN with a strong buy rating and lowers their REGN price target from $855.00 to $854.00, on Jul 9, 2026.
Robert Wasserman, a top 19% analyst from Benchmark upgrades REGN to a strong buy rating and announces their REGN price target of $185.00, on Jul 7, 2026.
You can dive deeper into what analysts are saying on the Regeneron Pharmaceuticals stock forecast page.
Metrics for Advanced REGN Traders
How is REGN performing as a company?
Last year, REGN earnings were $4.33B. In the last 5 year, REGN's earnings have grown by -6.56% per year. This was slower than the Biotechnology industry average of 9.7%.
Last year, REGN revenue was $15.53B. Over the past five year, REGN's revenue has increased by 4.64% per year. This was slower than the Biotechnology industry average of 23.69%.
You can research REGN's earnings and revenue performance here.
Who is buying/selling REGN?
In the last year, executives and large shareholders at REGN have sold more shares than they have bought.
Joseph J. Larosa, CLO;EVP of REGN, was the latest REGN insider to buy. They bought $4,690,741.44 worth of REGN shares on Aug 19, 2026.
Get more info about who owns REGN shares here.
Can I get consistent income from REGN stock?
Regeneron Pharmaceuticals pays a dividend of 0.47%, compared to the Biotechnology industry's average dividend yield of 1.8%. If you owned $1,000 of REGN stock, you would have been paid $4.66 last year.
Find more info about Regeneron Pharmaceuticals dividend yield and history here.
What others are saying about REGN
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your REGN buy order
There are two primary options:
- Market order: A market order is an order to buy or sell a stock at the best available price.
Market orders are generally fine for most investors. - Limit order: A limit order allows you to buy or sell a security at a specific price (or better).
If you want to ensure you're buying or selling at an exact price, use a limit order.
Hit the Open button and your broker will execute your order.
If you want additional assistance buying stocks on eToro, watch the how to video below:
Step 6: Get key alerts regarding your REGN investment
Now that you own some REGN shares, you'll want to keep up with your new investment.
Make a watchlist to track the latest developments regarding your REGN stock.
REGN Feed
How to Buy Stock in Regeneron Pharmaceuticals
To summarize, here are the 6 steps you need to take to buy Regeneron Pharmaceuticals stock right now:
- Figure out where to buy Regeneron Pharmaceuticals stock
- Create your brokerage account
- Deposit funds into your brokerage account
- Research Regeneron Pharmaceuticals stock
- Make your REGN buy order
- Get key alerts regarding your REGN investment
If you are looking for a brokerage account, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep an eye on your new investment in Regeneron Pharmaceuticals, click the button below.
More Stock Buying Guides You Might Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.